SCHEMBL7521699

SCHEMBL7521699

Cn1c(C=C2SC(=O)NC2=O)ccc1-c1nc2cc(Cl)c(Cl)cc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.44
GSK3B P49841 2/20 0.40
PIM1 P11309 4/20 0.39
PIM2 Q9P1W9 3/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
GLS O94925 1/20 0.37
GLS2 Q9UI32 1/20 0.37
CCR2 P41597 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
INSR P06213 1/20 0.37
RHEB Q15382 1/20 0.37
PIK3CD O00329 1/20 0.37
CSNK2A2 P19784 1/20 0.37
MAOB P27338 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7521696 1.00 IGF1R (0.44) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7516068 0.82 IGF1R (0.48) IGF1RPIM1PIM2NPC1RAB9A
SCHEMBL7516066 0.82 IGF1R (0.48) IGF1RPIM1PIM2NPC1RAB9A
SCHEMBL7516823 0.79 IGF1R (0.56) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7516825 0.79 IGF1R (0.56) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7516400 0.79 RHEB (0.46) NPC1RAB9AHTTCCR2HRH4
SCHEMBL7511049 0.78 IGF1R (0.46) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7511054 0.78 IGF1R (0.46) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7520443 0.76 IGF1R (0.43) IGF1RPIM1PIM2NPC1RAB9A
SCHEMBL7520438 0.76 IGF1R (0.43) IGF1RPIM1PIM2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 IGF1R 1097/4885GSK3B 1579/4885PIM1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.